Six months after a typical DSO acquisition, the same software is running three different ways across integrated locations. Same tool. Same onboarding session. Different workflows by provider, by region, and sometimes by operatory.
Consistent, measurable behavior across every location is what separates a good quarter from a regional variance conversation. COOs who treat Vision AI deployment as a structured change management project from day one, with defined success criteria before anyone goes live, are the ones hitting adoption KPIs at 60 to 90 days.
Where production loss actually comes from
Two failure modes show up consistently across DSO software deployments. The first is provider resistance: dentists and hygienists who don't see the immediate workflow benefit opt out quietly, location by location, until the tool has a 40% utilization rate that no one officially reported. The second is training variance: regional managers deliver onboarding differently, some locations get two hours of hands-on time and some get twenty minutes, and there's no standard to audit against.
When providers skip AI-assisted analysis, the downstream effects compound. Payer documentation quality drops because the AI-assisted findings that support clinical necessity aren't being captured. Case acceptance suffers because patients aren't seeing the visualizations that make treatment decisions concrete. And the COO is left with a production report that shows regional variance but no clear cause.
"We trained everyone" is not an adoption criterion. A location that completed training and a location that's actively using Vision AI on every relevant patient are not equivalent, and treating them as equivalent is where most rollouts quietly stall.
A phased rollout that protects production
Overjet's deployment model for Vision AI runs in three phases, each with exit criteria before the next begins.
Phase one is a pilot at one or two locations. The goal isn't to prove the technology works. It's to establish a measurable baseline: scan completion rates, provider usage frequency, documentation quality, and production figures before and after go-live. That baseline becomes the standard every subsequent location is measured against.
Phase two is controlled expansion. New locations are added in cohorts, not all at once. Each cohort has explicit go/no-go criteria tied to actual usage data from phase one, so expansion decisions are driven by performance, not by a calendar date. Production is tracked at each phase boundary. A location that dips gets attention before the dip becomes a trend.
Phase three is full rollout, by which point the playbook is documented and field-tested. Regional managers aren't improvising. They're executing a process that already produced results.
This structure gives COOs something most technology deployments don't: a defined intervention point at every stage rather than a single post-launch review three months later.
Role-specific enablement and regional accountability
A single all-staff training session produces a single moment of awareness. It doesn't produce consistent behavior across 30 locations six weeks later.
Dentists, hygienists, and front office staff each interact with Vision AI at different points in the patient visit. A dentist's enablement needs to focus on reading AI-assisted findings and integrating them into the diagnosis conversation. A hygienist's enablement centers on perio workflow and documentation. Front office enablement is about treatment presentation and insurance documentation support. Delivering the same session to all three produces the same inconsistency the rollout was designed to prevent.
Overjet's implementation team supports a site champion at each location. That champion owns adoption performance, serves as the first point of contact for provider questions, and gives the COO a named, accountable contact at every site. When outcomes are tracked by location and every location has an owner, regional variance becomes visible and manageable. COOs can identify which sites need intervention, act before one location's slow adoption pulls regional numbers down, and build a comparison dataset that makes future rollouts faster.
The structure that makes it replicable
DSO COOs who hit 60 to 90 day adoption KPIs share one common approach: they define what success looks like before deployment begins, build the rollout in phases with explicit performance gates, and assign accountability at the location level. That structure is what makes a deployment replicable across 10 locations or 100.
Book a Demo to see how Overjet's implementation model works in practice.
Frequently Asked Questions
How long does a Vision AI rollout typically take for a DSO?
Most DSOs complete the pilot phase within two to four weeks. Controlled expansion timelines depend on cohort size and regional complexity, but organizations that follow a phased model with defined go/no-go criteria typically reach full rollout within 60 to 90 days.
How do we measure provider adoption without adding more management overhead?
Vision AI produces usage data by provider and location that COOs can track without requiring additional manager involvement. Scan completion rates, AI-assisted finding frequency, and documentation quality are all measurable at the platform level. The site champion model keeps accountability at the location without creating a new layer of regional oversight.
What happens to production during the transition period?
Phased deployments are specifically designed to protect production. Piloting at one or two locations first means the majority of your locations stay in their current workflow while the model is being validated. Production benchmarks set during the pilot give you a realistic target for each subsequent cohort, so you're not setting expectations based on best-case assumptions.
How is Vision AI different from the AI tools we already have in our imaging software?
Most imaging platforms include some form of AI detection, but detection alone isn't the same as a clinical workflow built around AI-assisted findings. Vision AI is FDA-cleared across 11 indications, produces annotated visualizations that support patient treatment conversations, and generates documentation that holds up to payer review. It's also part of a broader platform covering insurance verification, voice documentation, and credentialing, so it connects to the operational workflows COOs are already trying to standardize.
